eve that VERU-944 would be favored over Clomid by clinicians for its favorable properties. VERU-944 can tap into a substantial market We note that Clomid is one of the cheapest drugs in the market and is listed in WHO's List of Essential medicine list (as a female fertility drug) that gives it a cred

enefit from the good name of Clomid and can establish a market in men with ADT from prostate cancer. On the other hand. we also feel that replacing Clomid, which has already been in off-label use, to become the new standard would take substantial efforts. Also, we feel that the differentiation from Cl